Trial Profile
Effect of ranibizumab on clotting time, plasma fibrinogen levels and blood viscosity in patients with macular choroidal neovascularization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Myopia
- Focus Adverse reactions
- 12 Jul 2016 New trial record